| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Hoffmann-La Roche |
| Information provided by: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT00048945 |
Purpose
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
| Condition | Intervention | Phase |
|
Chronic Hepatitis B |
Drug: PEGASYS |
Phase III |
| MedlinePlus related topics: | Hepatitis Hepatitis B |
| ChemIDplus related topics: | Peginterferon Alfa-2a Hepatitis B Vaccines |
| Study Type: | Interventional |
| Study Design: | Treatment |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations |
Show 74 Study Locations |
| Hoffmann-La Roche |
More Information
| Study ID Numbers: | WV16240 |
| First Received: | November 12, 2002 |
| Last Updated: | August 11, 2005 |
| ClinicalTrials.gov Identifier: | NCT00048945 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
